Preclinical development of AMG 139, a human antibody specifically targeting IL-23-Reference-Cited by-同舟云学术

Preclinical development of AMG 139, a human antibody specifically targeting IL-23

Published:2014-12-15 Issue:1 Volume:172 Page:159-172
ISSN:0007-1188
Container-title:British Journal of Pharmacology
language:en
Short-container-title:Br J Pharmacol

Author:

Köck K¹,Pan W J¹,Gow J M¹,Horner M J²,Gibbs J P¹,Colbert A¹,Goletz T J³,Newhall K J³,Rees W A³,Sun Y⁴,Zhang Y⁴,O'Neill J C⁵,Umble-Romero A N¹,Prokop S P¹,Krill C D³,Som L³,Buntich S A²,Trimble M W⁶,Tsuji W H³,Towne J E⁴

Affiliation:

1. Pharmacokinetics and Drug Metabolism; Amgen Inc.; Seattle WA USA

2. Comparative Biology and Safety Sciences; Amgen Inc.; Thousand Oaks CA USA

3. Medical Sciences; Amgen Inc.; Seattle WA USA

4. Inflammation Discovery Research; Amgen Inc.; Seattle WA USA

5. Biologic Optimization; Amgen Inc.; Seattle WA USA

6. Covance Laboratories Inc.; Madison WI USA

Funder

Amgen

Publisher

Wiley

Subject

Pharmacology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bph.12904/fullpdf

Reference68 articles.

1. The Concise Guide to PHARMACOLOGY 2013/14: Overview;Alexander;Br J Pharmacol,2013a

2. The Concise Guide to PHARMACOLOGY 2013/14: Catalytic receptors;Alexander;Br J Pharmacol,2013b

3. Th17: the third member of the effector T cell trilogy;Bettelli;Curr Opin Immunol,2007

4. IL-1RL2 and its ligands contribute to the cytokine network in psoriasis;Blumberg;J Immunol,2010

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Old and New Biologics and Small Molecules in Inflammatory Bowel Disease: Anti-interleukins;The Korean Journal of Gastroenterology;2024-08-25

2. The JAK-STAT pathway: from structural biology to cytokine engineering;Signal Transduction and Targeted Therapy;2024-08-21

3. JNJ-77242113, a highly potent, selective peptide targeting the IL-23 receptor, provides robust IL-23 pathway inhibition upon oral dosing in rats and humans;Scientific Reports;2024-07-30

4. Long-term safety of brazikumab in the open-label period of a randomized phase 2a study of patients with Crohn’s disease;BMC Gastroenterology;2023-12-20

5. Emerging Therapies for Ulcerative Colitis: Updates from Recent Clinical Trials;Clinical and Experimental Gastroenterology;2023-08